olfactory receptor family 2 subfamily B member 2Genealiases: OR2B2Q · OR2B9 · OR6-1 · dJ193B12.4 · hs6M1-10
Q-omics provides the consensus-scored OR2B2 profile across patient tissues and cancer cell-line models. OR2B2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, OR2B2 is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, OR2B2 RNA expression shows 7,941 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, BRCA, and LSCC as cancer lineages where OR2B2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR2B2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR2B2 survival associations across molecular data types. OR2B2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR2B2 RNA expression–survival associations across cancer types. High OR2B2 expression shows unfavorable associations in ACC, PAAD, KIRC, MESO, THCA and CHOL. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for OR2B2 RNA expression.
This table summarizes OR2B2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for OR2B2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR2B2 shows higher tumor expression in BRCA, UCEC and LIHC. The BRCA box plot shows higher OR2B2 RNA expression in tumor versus normal tissue (log2 FC = +0.080, t-test p = .001).
This table shows molecular features associated with OR2B2 in patient tissues and cancer cell lines. In patient samples, OR2B2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, OR2B2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_SCLC.
